Skip to main content
S&P 5007,632.76+1.07%DOW51,813.43+0.68%NASDAQ26,389.98+1.58%BTC$76,546.00+1.11%ETH$2,459.72+2.90%GOLD$4,407.20+0.45%OIL$101.25-1.15%
Smart Investors Daily
FE

NASDAQ · FEMY

Femasys Inc.

Healthcare · Medical - Instruments & Supplies

$2.54

Down-$0.03 (-1.18%)

Updated Sep 17, 2026, 4:44 PM

SID Score

5.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
25.19M
P/E ratio
-1.77
Dividend yield
0.00%
52-week range
$0.33 – $7.60
Volume
79.42K
Avg. volume
8.09M

Price performance

FEMY price history

1M range · 20 trading sessions · Daily adjusted prices

FEMY closed at $2.54 after 20 trading sessions, down 6.27% for the selected period.

Last close
$2.54
Period change
-6.27%
Period low
$2.54
Period high
$3.43
Daily close
View OHLC price history
FEMY OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 16, 2026$2.61$2.7356$2.5094$2.5479.42K
Sep 15, 2026$2.67$2.7382$2.50$2.5671.58K
Sep 14, 2026$2.84$2.848$2.59$2.6729.81K
Sep 11, 2026$2.81$2.8255$2.74$2.7816.2K
Sep 10, 2026$2.90$2.95$2.68$2.7435.53K
Sep 9, 2026$2.71$2.84$2.67$2.8346.73K
Sep 8, 2026$2.99$3.0858$2.60$2.68198.41K
Sep 4, 2026$3.03$3.063$2.93$2.9872.93K
Sep 3, 2026$3.10$3.1796$3.0101$3.0656.72K
Sep 2, 2026$3.26$3.39$3.02$3.10140.71K
Sep 1, 2026$3.34$3.425$3.2132$3.2667K
Aug 31, 2026$3.22$3.44$3.10$3.43231K
Aug 28, 2026$2.79$3.3499$2.74$3.20534.51K
Aug 27, 2026$2.93$3.09$2.73$2.79192.8K
Aug 26, 2026$2.88$3.00$2.83$2.92110.8K
Aug 25, 2026$3.00$3.06$2.81$2.85213.29K
Aug 24, 2026$2.94$3.08$2.86$2.98298.71K
Aug 21, 2026$2.64$3.12$2.64$2.96584.93K
Aug 20, 2026$2.59$2.82$2.43$2.73961.67K
Aug 19, 2026$3.00$3.69$2.27$2.7136.72M

Latest FEMY news

The latest Smart Investors Daily articles mentioning FEMY.

Stock researchCompany · Overview

FEMY research

Overview

Company profile and research snapshot.

Company profile

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
FEMY recent ratings
DateFirmRatingTarget
Aug 18, 2026Lake StreetBuy—
Aug 14, 2026Maxim GroupBuy—
Mar 3, 2026Lake StreetBuy—
Nov 20, 2025Laidlaw & Co.Buy—
Aug 11, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 9, 2026

Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio

Collaboration provides dedicated patient financing for Femasys fertility solutions, helping reduce financial barriers to care across OB/GYN practices and fertility centersATLANTA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today a partnership with CapexMD

Yahoo · Aug 26, 2026

Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations

-- For the first time, OB/GYNs within the UNC Health system will be able to offer women FemVue® fertility evaluation and FemaSeed as a first-line treatment option -- ATLANTA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today a partnership with UNC Health to

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By